Rocket Pharmaceuticals, Inc.

DB:9IP1 Stock Report

Market Cap: €623.1m

Rocket Pharmaceuticals Valuation

Is 9IP1 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

4/6

Valuation Score 4/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Book vs Peers

  • Price-To-Book vs Industry

  • Price-To-Book vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 9IP1 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Discounted Cash Flow
Simply Wall St
€318.99
Fair Value
98.3% undervalued intrinsic discount
16
Number of Analysts

Below Fair Value: 9IP1 (€5.36) is trading below our estimate of fair value (€318.99)

Significantly Below Fair Value: 9IP1 is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 9IP1?

Key metric: As 9IP1 is unprofitable and pre-revenue we use its Price-To-Book Ratio for relative valuation analysis.

The above table shows the Price to Book ratio for 9IP1. This is calculated by dividing 9IP1's market cap by their current book value.
What is 9IP1's PB Ratio?
PB Ratio1.7x
BookUS$412.14m
Market CapUS$700.30m

Price to Book Ratio vs Peers

How does 9IP1's PB Ratio compare to its peers?

The above table shows the PB ratio for 9IP1 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PBEstimated GrowthMarket Cap
Peer Average2.5x
FYB Formycon
0.9x78.63%€403.5m
BIO3 Biotest
2.3xn/a€1.4b
HPHA Heidelberg Pharma
6.1x-14.02%€147.7m
2INV 2invest
0.8xn/a€70.0m
9IP1 Rocket Pharmaceuticals
1.7x55.54%€700.3m

Price-To-Book vs Peers: 9IP1 is good value based on its Price-To-Book Ratio (1.7x) compared to the peer average (2.5x).

Price to Book Ratio vs Industry

How does 9IP1's PB Ratio compare vs other companies in the DE Biotechs Industry?

4 CompaniesPrice / BookEstimated GrowthMarket Cap
V9Z Aceragen
0.1xn/aUS$3.12m
V9Z Aceragen
0.1xn/aUS$2.18m
MDG1 Medigene
0.1x14.15%US$2.07m
O7P NeuBase Therapeutics
0.1xn/aUS$1.39m
No more companies available in this PB range
9IP1 1.7xIndustry Avg. 2.4xNo. of Companies4PB00.61.21.82.43+
4 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Book vs Industry: 9IP1 is good value based on its Price-To-Book Ratio (1.7x) compared to the European Biotechs industry average (2.5x).

Price to Book Ratio vs Fair Ratio

What is 9IP1's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

9IP1 PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio1.7x
Fair PB Ration/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate 9IP1's Price-To-Book Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 9IP1 forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current€5.32
€31.84
+498.27%
30.22%€49.33€11.66n/a16
May ’26€5.99
€35.25
+488.60%
21.89%€48.14€25.38n/a15
Apr ’26€5.75
€38.43
+568.58%
20.84%€50.81€26.79n/a15
Mar ’26€8.68
€39.46
+354.65%
21.35%€53.03€27.96n/a14
Feb ’26€9.94
€41.36
+316.23%
26.87%€62.42€27.85n/a15
Jan ’26€10.83
€41.82
+286.16%
25.92%€62.49€27.88n/a16
Dec ’25€13.22
€44.16
+234.01%
21.50%€61.35€27.37n/a14
Nov ’25€14.93
€43.87
+193.94%
20.33%€60.03€28.63n/a14
Oct ’25€16.21
€43.20
+166.60%
20.98%€59.55€28.40n/a13
Sep ’25€16.57
€43.20
+160.73%
20.98%€59.55€28.40n/a13
Aug ’25€22.18
€43.45
+95.88%
19.35%€59.60€28.42n/a13
Jul ’25€19.10
€46.32
+142.49%
15.01%€60.68€34.54n/a13
Jun ’25€19.42
€46.42
+139.04%
14.28%€60.26€36.15n/a13
May ’25€20.26
€46.72
+130.61%
14.36%€60.37€36.22€5.9913
Apr ’25€24.74
€47.29
+91.16%
13.09%€59.98€35.99€5.7512
Mar ’25€27.00
€47.29
+75.16%
13.09%€59.98€35.99€8.6812
Feb ’25€26.60
€47.02
+76.78%
14.29%€59.74€34.00€9.9412
Jan ’25€27.93
€48.43
+73.41%
14.29%€60.83€34.63€10.8312
Dec ’24€21.37
€48.43
+126.64%
14.29%€60.83€34.63€13.2212
Nov ’24€17.90
€48.69
+172.00%
14.74%€60.96€36.57€14.9312
Oct ’24€19.48
€47.71
+144.91%
13.50%€60.57€36.34€16.2110
Sep ’24€14.43
€46.51
+222.39%
13.88%€55.72€35.63€16.5711
Aug ’24€16.37
€49.23
+200.74%
17.23%€68.03€35.38€22.1811
Jul ’24€18.61
€47.87
+157.22%
19.78%€68.17€31.81€19.1012
Jun ’24€19.30
€47.87
+148.09%
19.78%€68.17€31.81€19.4212
May ’24€15.99
€47.80
+198.91%
20.62%€68.06€29.95€20.2612
AnalystConsensusTarget
Consensus Narrative from 16 Analysts
€29.52
Fair Value
81.8% undervalued intrinsic discount
16
Number of Analysts

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/05/19 17:42
End of Day Share Price 2025/05/19 00:00
Earnings2025/03/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Rocket Pharmaceuticals, Inc. is covered by 24 analysts. 15 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Konstantinos BiliourisBMO Capital Markets Equity Research
Jason ZemanskyBofA Global Research
Whitney IjemCanaccord Genuity